Publications
- Understanding the positive benefit: risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program2017 | First Faculty of Medicine, Second Faculty of Medicine
- Treatment of multiple sclerosis with oral cladribine: results of clinical trials2017 | First Faculty of Medicine
- Alemtuzumab in the therapy of patients with relapsing-remitting multiple sclerosis2016 | First Faculty of Medicine
- Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use2015 | First Faculty of Medicine
- Missed diagnosis of Fabry disease: should we screen patients with multiple sclerosis?2024 | First Faculty of Medicine
- Multiple Sclerosis and Microbiome2022 | First Faculty of Medicine, Faculty of Physical Education and Sport
- To be or not to be vaccinated: The risk of MS or NMOSD relapse after COVID-19 vaccination and infection2022 | First Faculty of Medicine
- Long-term management of oral cladribine treatment in multiple sclerosis2021 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Faculty of Medicine in Pilsen
- Pregnancy and multiple sclerosis from a neurologist's point of view2018 | First Faculty of Medicine, Second Faculty of Medicine
- Komentář: Post hoc analýza studie CLARITY - účinnost perorálně podávaného kladribinu u pacientů s vysokou aktivitou relabující-remitující RS2018 | First Faculty of Medicine
Loading network view...